Global Reach, Local Impact in the MENA Region: ADCAN Pharma Signs a first complex generic molecule and a Strategic Partnership MOU with Lotus at CPHI!
We are delighted to announce a new partnership with Lotus, a prominent pharmaceutical company from Taiwan, signed under the patronage of EDE during the bustling CPHI Milan event! ADCAN Pharma has signed a licensing agreement for a first complex generic asset and, building on this, a Memorandum of Understanding (MOU) for a broader strategic partnership. Together, these agreements will expand our complex generics portfolio across the MENA region.
“Signing our first licensing agreement with Lotus, together with an MOU for a broader strategic partnership, is an exciting development for ADCAN Pharma. It highlights our dedication to bringing differentiated complex generic solutions in UAE, Saudi Arabia, Iraq, Libya and Gulf region. By partnering with a reputable company like Lotus, we are strengthening our ability to provide cutting-edge treatments to patients in MENA. We are eager to progress this collaboration and make a tangible impact on patients’ lives across the region.” Fokion Sinis, CEO of ADCAN Pharma
“We are pleased to establish this strategic B2B partnership with ADCAN for the MENA region. Through this collaboration, we aim to broaden patient access to Lotus’s products and strengthen our reach in these markets. We look forward to building a successful partnership that supports the region’s healthcare needs.” Petar Vazharov, CEO Lotus
This first licensing agreement and the strategic partnership MOU reflect our continued commitment to expanding a robust complex specialty generics portfolio and our dedication to sourcing high-value treatments from around the world. We are excited to work with Lotus to bring new hope and advanced, high-quality treatment options to patients across the MENA region.
